
TY  - JOUR
TI  - BACK PAIN
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_3.x
DO  - doi:10.1111/j.1479-8077.2006.00199_3.x
SP  - A26
EP  - A31
PY  - 2006
ER  - 

TY  - JOUR
TI  - BONE DISEASES OTHER THAN OSTEOPOROSIS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_4.x
DO  - doi:10.1111/j.1479-8077.2006.00199_4.x
SP  - A31
EP  - A33
PY  - 2006
ER  - 

TY  - JOUR
TI  - CELL RECEPTOR-LIGAND INTERACTION, SIGNALING AND ACTIVATION
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_6.x
DO  - doi:10.1111/j.1479-8077.2006.00199_6.x
SP  - A39
EP  - A39
PY  - 2006
ER  - 

TY  - JOUR
TI  - CYTOKINES AND INFLAMMATORY MEDIATORS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_7.x
DO  - doi:10.1111/j.1479-8077.2006.00199_7.x
SP  - A39
EP  - A45
PY  - 2006
ER  - 

TY  - JOUR
TI  - HEALTH SERVICES, ECONOMICS AND OUTCOME MEASURES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_12.x
DO  - doi:10.1111/j.1479-8077.2006.00199_12.x
SP  - A68
EP  - A78
PY  - 2006
ER  - 

TY  - JOUR
TI  - HUMORAL ASPECTS OF AUTOIMMUNE DISEASES
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_13.x
DO  - doi:10.1111/j.1479-8077.2006.00199_13.x
SP  - A79
EP  - A80
PY  - 2006
ER  - 

TY  - JOUR
TI  - OTHERS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_21.x
DO  - doi:10.1111/j.1479-8077.2006.00199_21.x
SP  - A142
EP  - A159
PY  - 2006
ER  - 

TY  - JOUR
TI  - SYSTEMIC LUPUS ERYTHEMATOSUS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_30.x
DO  - doi:10.1111/j.1479-8077.2006.00199_30.x
SP  - A253
EP  - A274
PY  - 2006
ER  - 

TY  - JOUR
TI  - VASCULITIS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_31.x
DO  - doi:10.1111/j.1479-8077.2006.00199_31.x
SP  - A274
EP  - A278
PY  - 2006
ER  - 

TY  - JOUR
AU  - TRIPODI, A.
AU  - ANSTEE, Q. M.
AU  - SOGAARD, K. K.
AU  - PRIMIGNANI, M.
AU  - VALLA, D. C.
TI  - Hypercoagulability in cirrhosis: causes and consequences1
JO  - Journal of Thrombosis and Haemostasis
VL  - 9
IS  - 9
SN  - 1538-7933
UR  - https://doi.org/10.1111/j.1538-7836.2011.04429.x
DO  - doi:10.1111/j.1538-7836.2011.04429.x
SP  - 1713
EP  - 1723
KW  - chronic liver disease
KW  - factor VIII
KW  - protein C
KW  - thrombin
KW  - thrombomodulin
PY  - 2011
AB  - Summary.? Decreased levels of most coagulation factors and thrombocytopenia are the main haemostatic abnormalities of cirrhosis. As a consequence, this condition was, until recently, considered as the prototype acquired coagulopathy responsible for bleeding. However, recent evidence suggests that it should, rather, be regarded as a condition associated with normal or even increased thrombin generation. The bleeding events that occur in these patients should, therefore, be explained by the superimposed conditions that frequently occur in this setting. Due to elevated levels of factor VIII (procoagulant driver) in combination with decreased protein C (anticoagulant driver), which are typically found in patients with cirrhosis, a procoagulant imbalance, defined as a partial resistance to the in vitro anticoagulant action of thrombomodulin, can be demonstrated. Whether this in vitro hypercoagulability is truly representative of what occurs in vivo remains to be established. However, the hypothesis that it may have clinical consequences is attractive and deserves attention. The possible consequences that we discuss herein include whether (i) cirrhosis is a condition associated with increased risk of venous thromboembolism or portal vein thrombosis; (ii) the hypercoagulability associated with cirrhosis has any other role outside coagulation (i.e. progression of liver fibrosis); and (iii) anticoagulation should be used in cirrhosis. Although apparently provocative, considering anticoagulation as a therapeutic option in patients with cirrhosis is now supported by a rationale of increasing strength. There may be subgroups of patients who benefit from anticoagulation to treat or prevent thrombosis and to slow hepatic fibrosis. Clinical studies are warranted to explore these therapeutic options.
ER  - 

TY  - JOUR
AU  - Tomescu, C.
AU  - Abdulhaqq, S.
AU  - Montaner, L. J.
TI  - Evidence for the innate immune response as a correlate of protection in human immunodeficiency virus (HIV)-1 highly exposed seronegative subjects (HESN)
JO  - Clinical & Experimental Immunology
VL  - 164
IS  - 2
SN  - 0009-9104
UR  - https://doi.org/10.1111/j.1365-2249.2011.04379.x
DO  - doi:10.1111/j.1365-2249.2011.04379.x
SP  - 158
EP  - 169
KW  - dendritic cells
KW  - HIV-1 exposed seronegative
KW  - intravenous drug-user
KW  - natural killer cells
PY  - 2011
AB  - Summary The description of highly exposed individuals who remain seronegative (HESN) despite repeated exposure to human immunodeficiency virus (HIV)-1 has heightened interest in identifying potential mechanisms of HIV-1 resistance. HIV-specific humoral and T cell-mediated responses have been identified routinely in HESN subjects, although it remains unknown if these responses are a definitive cause of protection or merely a marker for exposure. Approximately half of HESN lack any detectible HIV-specific adaptive immune responses, suggesting that other mechanisms of protection from HIV-1 infection also probably exist. In support of the innate immune response as a mechanism of resistance, increased natural killer (NK) cell activity has been correlated with protection from infection in several high-risk cohorts of HESN subjects, including intravenous drug users, HIV-1 discordant couples and perinatally exposed infants. Inheritance of protective NK KIR3DL1high and KIR3DS1 receptor alleles have also been observed to be over-represented in a high-risk cohort of HESN intravenous drug users and HESN partners of HIV-1-infected subjects. Other intrinsic mechanisms of innate immune protection correlated with resistance in HESN subjects include heightened dendritic cell responses and increased secretion of anti-viral factors such as ?-chemokines, small anti-viral factors and defensins. This review will highlight the most current evidence in HESN subjects supporting the role of epithelial microenvironment and the innate immune system in sustaining resistance against HIV-1 infection. We will argue that as a front-line defence the innate immune response determines the threshold of infectivity that HIV-1 must overcome to establish a productive infection.
ER  - 

TY  - JOUR
TI  - ORTHOPAEDIC SURGERY AND SPORTS MEDICINE
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_18.x
DO  - doi:10.1111/j.1479-8077.2006.00199_18.x
SP  - A101
EP  - A108
PY  - 2006
ER  - 

TY  - JOUR
TI  - RHEUMATOID ARTHRITIS – CLINICAL ASPECTS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_23.x
DO  - doi:10.1111/j.1479-8077.2006.00199_23.x
SP  - A167
EP  - A188
PY  - 2006
ER  - 

TY  - JOUR
TI  - SYSTEMIC LUPUS ERYTHEMATOSUS – AETIOLOGY AND PATHOGENESIS/ANIMAL MODELS
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_29.x
DO  - doi:10.1111/j.1479-8077.2006.00199_29.x
SP  - A247
EP  - A253
PY  - 2006
ER  - 

TY  - JOUR
TI  - CARTILAGE IN BONE BIOLOGY AND PATHOPHYSIOLOGY
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_5.x
DO  - doi:10.1111/j.1479-8077.2006.00199_5.x
SP  - A33
EP  - A39
PY  - 2006
ER  - 

TY  - JOUR
TI  - The Best for Women Joint International Conference
JO  - Australian and New Zealand Journal of Obstetrics and Gynaecology
VL  - 42
IS  - 4
SN  - 0004-8666
UR  - https://doi.org/10.1111/j.0004-8666.2002.00419.x
DO  - doi:10.1111/j.0004-8666.2002.00419.x
SP  - 419
EP  - 458
PY  - 2002
ER  - 

TY  - JOUR
TI  - #ANZACA2019 – 16th Annual Meeting of the Australian and New Zealand Association of Clinical Anatomists “The Modern Anatomist: Where Are We Now and Where are We Headed? 4–6 December 2019 The University of Western Australia, Perth, Australia
JO  - Clinical Anatomy
JA  - Clin Anat
VL  - n/a
IS  - n/a
SN  - 0897-3806
UR  - https://doi.org/10.1002/ca.23544
DO  - doi:10.1002/ca.23544
ER  - 

TY  - JOUR
AU  - Gala, Salvador
AU  - Fulcher, David A
C7  - 19856
TI  - 3.4 How HIV leads to autoimmune disorders
JO  - Journal of the International AIDS Society
JA  - Medical Journal of Australia
VL  - 17
IS  - 4S3
SN  - 1758-2652
UR  - https://doi.org/10.7448/IAS.17.4.19856
DO  - doi:10.7448/IAS.17.4.19856
SP  - 19856
PY  - 2014
AB  - HIV-related autoimmune disorders tend to occur in the early phase of HIV infection, while the immune system is still relatively competent, and they may be the presenting manifestation of HIV infection itself.
ER  - 

TY  - JOUR
TI  - MYOPATHIES AND SOFT TISSUE RHEUMATISM INCLUDING FIBROMYALGIA
JO  - Medical Journal of Australia
VL  - 164
IS  - 4
SN  - 0025-729X
UR  - https://doi.org/10.5694/j.1326-5377.1996.tb94145.x
DO  - doi:10.5694/j.1326-5377.1996.tb94145.x
SP  - 224
EP  - 226
PY  - 1996
ER  - 

TY  - JOUR
TI  - MYOPATHIES AND SOFT TISSUE RHEUMATISM INCLUDING FIBROMYALGIA
JO  - APLAR Journal of Rheumatology
VL  - 9
IS  - s1
SN  - 0219-0494
UR  - https://doi.org/10.1111/j.1479-8077.2006.00199_17.x
DO  - doi:10.1111/j.1479-8077.2006.00199_17.x
SP  - A99
EP  - A101
PY  - 2006
ER  - 
